Publications by authors named "W Margas"
Article Synopsis
- The Phase 3 XTEND-1 trial demonstrated that efanesoctocog alfa provides better bleed protection than standard factor VIII (FVIII) replacement therapies for patients with severe hemophilia A.
- A systematic literature review was conducted to compare bleeding outcomes between efanesoctocog alfa and different types of FVIII therapies, using statistical methods to analyze annualized bleeding rates (ABRs).
- Results showed that efanesoctocog alfa was linked to significantly fewer annual bleeds, averaging 2.2 fewer versus extended half-life therapies and 3.6 fewer versus standard therapies.
Introduction: The phase 3 XTEND-1 trial (NCT04161495) demonstrated that efanesoctocog alfa prophylaxis provided superior bleed protection compared with pre-trial factor VIII (FVIII) prophylaxis in patients with severe haemophilia A. The aim of this study was to indirectly compare the efficacy of efanesoctocog alfa with non-factor replacement therapy emicizumab in adolescent and adult patients with severe haemophilia A without inhibitors.
Methods: A systematic literature review was conducted to identify phase 3 trials of emicizumab.
Impact of the COVID-19 pandemic on the conduct of clinical trials: a quantitative analysis.
J Mark Access Health Policy
August 2022
Background: Globally, healthcare has shouldered much of the socioeconomic brunt of the COVID-19 pandemic leading to numerous clinical trials suspended or discontinued.
Objective: To estimate the COVID-19 impact on the number of clinical trials worldwide.
Methods: Data deposited by 219 countries in the ClinicalTrials.
Background: Rivaroxaban and apixaban are the most widely used nonvitamin K oral anticoagulants (NOACs) in patients with venous thromboembolism (VTE). This meta-analysis evaluates the effectiveness and safety of both NOACs versus standard of care (SoC) in real-world practice.
Methods: Real-world evidence (RWE) studies were identified through a systematic literature review conducted between January 2012 and July 2020, using Embase, MEDLINE, and the websites of cardiological, hematological, and oncological associations.
Article Synopsis
- Necrotising enterocolitis (NEC) is a severe condition affecting up to 10% of very low birth weight infants and has high mortality rates, which can reach 60%.
- The study aims to determine if combining abdominal ultrasound (AUS) with abdominal radiography (AR) improves diagnosis and treatment speed for NEC in infants born before 32 weeks, analyzing data from 200 VLBW infants.
- The study has ethical approval and intends to share results through peer-reviewed journals and conferences, contributing to the understanding and management of NEC.